University of Turin, IT
UNITO will take responsibility for testing the role of specific molecular abnormalities in preclinical animal studies in WP4. They will work in close cooperation with the proteomic unit to accelerate the discovery of new biomarkers, and in close cooperation with interventional radiology and radiation oncology to select innovative strategies to treat TKI-resistant GIST patients. In addition, they will form collaborative relationships with radiation oncology and surgical oncology for multimodal treatment, and will work in close collaboration in the field of radiochemistry/ radiopharmacy.
Dr. Inghirami has extensive expertise in cellular biology, flow cytometry, immunology, molecular biology, and hematopathology. His current areas of research are the molecular mechanisms leading to ALK-mediated transformation, the development of specific drugs to inhibit ALK activity. Currently his group creates a centralised and fully automated clinical and research molecular oncology facility and generated many transgenic mouse models and in the last 18 mouths he has established a colony of NOD/Scid/IL2-/- mice, demonstrating the feasibilities of generating using primary human tumourgrafts.